Intervention Review

You have free access to this content

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease

  1. Kayleigh M Kew1,*,
  2. Alieksei Seniukovich2

Editorial Group: Cochrane Airways Group

Published Online: 10 MAR 2014

Assessed as up-to-date: 5 SEP 2013

DOI: 10.1002/14651858.CD010115.pub2


How to Cite

Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD010115. DOI: 10.1002/14651858.CD010115.pub2.

Author Information

  1. 1

    St George's, University of London, Population Health Research Institute, London, UK

  2. 2

    Grodno Clinic Hospital #2, Grodno, Belarus

*Kayleigh M Kew, Population Health Research Institute, St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK. kkew@sgul.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 10 MAR 2014

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Aykut Cilli, Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease, Current Infectious Disease Reports, 2015, 17, 1

    CrossRef

  2. 2
    James F. Donohue, Sally Worsley, Chang-Qing Zhu, Liz Hardaker, Alison Church, Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations, Respiratory Medicine, 2015, 109, 7, 870

    CrossRef

  3. 3
    Hong-Li Jiang, Hong-Xuan Chen, Wei Liu, Tao Fan, Guan-Jian Liu, Bing Mao, Is COPD associated with increased mortality and morbidity in hospitalized pneumonia? A systematic review and meta-analysis, Respirology, 2015, 20, 6
  4. 4
    Fulvio Braido, Giovanni Melioli, Mario Cazzola, Leonardo Fabbri, Francesco Blasi, Lorenzo Moretta, Giorgio Walter Canonica, Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation), Pulmonary Pharmacology & Therapeutics, 2015, 33, 75

    CrossRef

  5. 5
    Oriol Sibila, Natalia Soto-Gomez, Marcos I. Restrepo, The risk and outcomes of pneumonia in patients on inhaled corticosteroids, Pulmonary Pharmacology & Therapeutics, 2015, 32, 130

    CrossRef

  6. 6
    G. Deslée, Bronchopneumopathie chronique obstructive, Revue des Maladies Respiratoires Actualités, 2014, 6, 4, 16

    CrossRef

  7. 7
    David Price, Dorothy Keininger, Madlaina Costa-Scharplatz, Karen Mezzi, Maria Dimova, Yumi Asukai, Björn Ställberg, Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting, Respiratory Medicine, 2014, 108, 12, 1786

    CrossRef

  8. 8
    Lydia Finney, Matthew Berry, Aran Singanayagam, Sarah L Elkin, Sebastian L Johnston, Patrick Mallia, Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease, The Lancet Respiratory Medicine, 2014, 2, 11, 919

    CrossRef

  9. 9
    Daniel J Tan, Clinton J White, Julia AE Walters, E. Haydn Walters, Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease, The Cochrane Library,
  10. You have free access to this content10
    Kayleigh M Kew, Sofia Dias, Christopher J Cates, Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis, The Cochrane Library,
  11. 11
    Bernard McCarthy, Dympna Casey, Declan Devane, Kathy Murphy, Edel Murphy, Yves Lacasse, Pulmonary rehabilitation for chronic obstructive pulmonary disease, The Cochrane Library,